Alpha Tau Medical (NASDAQ:DRTS) outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the company’s most important trials are “coming to a head” over the coming months.
Levy said the company is focused on three key studies: ReSTART in recurrent cutaneous squamous cell carcinoma, the IMPACT pancreatic cancer trial in the U.S. and the REGAIN brain cancer study in the U.S. He described 2026 as a “very, very busy and catalyst-rich year” for the company.
